Swedish biopharmaceutical company Sobi has announced a strong second quarter for 2025, with total revenue increasing by 13%. The growth is propelled by significant gains in both its haematology and immunology portfolios. Despite incurring restructuring costs, the company achieved an improved adjusted EBITA margin, reflecting enhanced operational efficiency.